NewLink Genetics Corp. today announced that the international partnership studying the VSV-ZEBOV (Ebola) vaccine candidate in Guinea has released interim data suggesting that it is effective against Ebola in a large clinical trial. According to the announcement by the Ames-based company, the interim results suggest that the vaccine demonstrates efficacy within about 10 days of administration to a person without the infection. “We hope that the interim data published today contribute to the successful registration of our vaccine candidate, which we believe can play an important part in diminishing the threat of Ebola,” said Dr. Charles Link, chairman, CEO and chief scientific officer of NewLink Genetics.